丸美生物
(603983)
| 流通市值：195.89亿 | | | 总市值：195.89亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,694,566,806 | 2,032,128,563.24 | 1,358,091,398.2 | 1,121,728,940.78 |
| 应收票据及应收账款 | 57,054,102.2 | 44,998,454.03 | 63,431,126.49 | 79,378,003.72 |
| 其中：应收票据 | - | - | - | 820,000 |
| 应收账款 | 57,054,102.2 | 44,998,454.03 | 63,431,126.49 | 78,558,003.72 |
| 应收款项融资 | 1,430,000 | 1,430,000 | - | - |
| 预付款项 | 99,519,852.88 | 41,362,251.1 | 89,060,615.42 | 43,156,158.12 |
| 其他应收款合计 | 12,025,885.98 | 11,572,745.01 | 13,140,821.53 | 12,547,194.73 |
| 存货 | 243,011,003.87 | 219,658,341.31 | 191,293,771.02 | 177,403,003.77 |
| 一年内到期的非流动资产 | - | 44,084,931.52 | 248,131,410.94 | 246,118,123.28 |
| 其他流动资产 | 143,297,594.63 | 163,469,303.49 | 141,095,202.77 | 149,274,763.14 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,641,018,361.33 | 2,954,402,626.08 | 2,596,435,890.88 | 2,321,516,986.33 |
| 非流动资产: | | | | |
| 长期应收款 | 953,300 | 953,300 | - | - |
| 长期股权投资 | 180,655,821.89 | 165,655,582.9 | 60,500,550.56 | 60,501,330.16 |
| 投资性房地产 | 3,199,812.73 | 3,278,251.01 | 3,356,689.29 | 3,435,127.57 |
| 固定资产 | 474,447,372.19 | 475,595,007.8 | 451,879,506.32 | 447,849,778.27 |
| 在建工程 | 617,601,656.37 | 603,055,737.06 | 494,168,371.12 | 435,610,758.65 |
| 使用权资产 | 1,172,766.72 | 3,148,264.16 | 3,213,397.63 | 4,444,547.97 |
| 无形资产 | 694,683,381.32 | 699,162,245.19 | 705,003,763.3 | 709,738,134.82 |
| 长期待摊费用 | 16,615,742.17 | 1,741,298.16 | 1,962,823.13 | 2,457,933.34 |
| 递延所得税资产 | 85,611,942.55 | 91,846,317.66 | 61,703,374.36 | 60,353,362.51 |
| 其他非流动资产 | 63,829,056.51 | 63,725,464.79 | 56,784,325.05 | 267,234,443.88 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,138,770,852.45 | 2,108,161,468.73 | 1,838,572,800.76 | 1,991,625,417.17 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 4,779,789,213.78 | 5,062,564,094.81 | 4,435,008,691.64 | 4,313,142,403.5 |
| 流动负债: | | | | |
| 短期借款 | 510,000,000 | 790,104,166.67 | 248,783,750 | 248,323,750 |
| 应付票据及应付账款 | 285,207,054.4 | 359,240,825.46 | 353,423,620.59 | 271,874,208.55 |
| 其中：应付票据 | - | - | 130,000,000 | - |
| 应付账款 | 285,207,054.4 | 359,240,825.46 | 223,423,620.59 | 271,874,208.55 |
| 合同负债 | 189,806,404.62 | 195,122,115.12 | 197,375,032.18 | 193,823,635.84 |
| 应付职工薪酬 | 15,585,434.63 | 27,125,286.63 | 14,767,540.77 | 16,189,615.39 |
| 应交税费 | 51,784,896.89 | 50,691,869.86 | 36,124,467.91 | 37,728,311.11 |
| 其他应付款合计 | 113,537,751.89 | 158,013,863.69 | 101,010,947.81 | 121,101,024.57 |
| 一年内到期的非流动负债 | 996,327.69 | 2,362,855.76 | 2,124,498.5 | 2,322,812.98 |
| 其他流动负债 | 13,950,348.99 | 13,879,155.67 | 15,945,898.06 | 14,698,910.68 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,180,868,219.11 | 1,596,540,138.86 | 969,555,755.82 | 906,062,269.12 |
| 非流动负债: | | | | |
| 租赁负债 | 507,766.76 | 1,504,100.74 | 2,257,408.65 | 2,755,238.53 |
| 预计负债 | 360,000 | 360,000 | 360,000 | 360,000 |
| 递延收益 | 5,176,213.67 | 5,393,246.26 | 4,347,595.61 | 5,127,417.68 |
| 递延所得税负债 | 12,091,823.4 | 12,263,111.19 | 14,781,306.55 | 16,892,106.53 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 18,135,803.83 | 19,520,458.19 | 21,746,310.81 | 25,134,762.74 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,199,004,022.94 | 1,616,060,597.05 | 991,302,066.63 | 931,197,031.86 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 401,000,000 | 401,000,000 | 401,000,000 | 401,000,000 |
| 资本公积 | 760,997,417.99 | 760,997,417.99 | 760,454,706.74 | 760,454,706.74 |
| 其他综合收益 | -1,768,129.75 | -1,708,532.4 | -1,637,487.47 | -1,596,288.98 |
| 盈余公积 | 200,909,800 | 200,909,800 | 200,909,800 | 200,909,800 |
| 未分配利润 | 2,154,253,296.59 | 2,019,208,207.26 | 2,016,632,761.2 | 1,954,366,586.31 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,515,392,384.83 | 3,380,406,892.85 | 3,377,359,780.47 | 3,315,134,804.07 |
| 少数股东权益 | 65,392,806.01 | 66,096,604.91 | 66,346,844.54 | 66,810,567.57 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,580,785,190.84 | 3,446,503,497.76 | 3,443,706,625.01 | 3,381,945,371.64 |
| 负债和股东权益合计 | 4,779,789,213.78 | 5,062,564,094.81 | 4,435,008,691.64 | 4,313,142,403.5 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |